吉非替尼联合吉西他滨和顺铂化疗方案治疗晚期非小细胞肺癌患者的临床效果

Chemotherapy Effects of Gefitinib Combined with Gemcitabine and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer

目的探讨晚期非小细胞肺癌患者应用吉非替尼联合吉西他滨和顺铂化疗方案的治疗效果及对血清肿瘤标志物的影响。方法选取2018年4月至2019年3月北票市中心医院介入肿瘤科收治的76例非小细胞肺癌晚期患者作为研究对象,以入院病历号进行奇偶排序,分为两组,每组38例,对照组应用吉西他滨、顺铂化疗方案,试验组在对照组基础上加用吉非替尼,比较两组患者临床疗效、血清肿瘤标志物。结果试验组治疗有效率为73.69%,明显高于对照组的52.63%,差异有统计学意义(P<0.05);治疗后,试验组血清细胞角蛋白19片段(CYFRA21-1)、神经烯醇化酶(NSE)明显低于对照组,差异有统计学意义(P<0.05)。结论晚期非小细胞肺癌患者应用吉非替尼联合吉西他滨和顺铂化疗方案治疗能取得较好的临床疗效,有助于延缓肿瘤进展,降低肿瘤标志物中血清CYFRA21-1和NSE表达。

Objective To explore the chemotherapy effects of gefitinib combined with gemcitabine and cisplatin in advanced non-small cell lung cancer,and its effects on serum tumor markers.Methods A total of 76 patients with advanced NSCLC admitted to Interventional Oncology,Central Hospital of Beipiao City,from April 2018 to March 2019 were included in this study.According to the odd and even order of medical record number,they were divided into 2 groups,with 38 cases in each group.The control group was treated with gemcitabine and cisplatin.On this basis,gefitinib was used in the experimental group.The therapeutic effects and serum tumor markers were compared between the 2 groups.Results In terms of treatment efficiency,the experimental group was higher than the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of serum cytokeratin 19(CYFRA21-1)and neuroenolase(NSE)in the experimental group were lower than those in the control group and the difference was statistically significant(P<0.05).Conclusion The combination of gefitinib,gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer can achieve better clinical effects.It is helpful to delay the progression of tumor and reduce the expression level of CYFRA21-1 and NSE in serum of tumor markers.